elevance health inc. - ELV
ELV
Close Chg Chg %
346.78 2.64 0.76%
Closed Market
349.42
+2.64 (0.76%)
Volume: 1.62M
Last Updated:
Jul 8, 2025, 3:59 PM EDT
Company Overview: elevance health inc. - ELV
ELV Key Data
| Open $347.70 | Day Range 344.90 - 350.68 |
| 52 Week Range 343.75 - 567.17 | Market Cap $78.37B |
| Shares Outstanding 225.94M | Public Float 225.56M |
| Beta 0.61 | Rev. Per Employee N/A |
| P/E Ratio 13.53 | EPS $25.77 |
| Yield 192.57% | Dividend $1.71 |
| EX-DIVIDEND DATE Jun 10, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.72M |
ELV Performance
| 1 Week | -0.28% | ||
| 1 Month | -11.82% | ||
| 3 Months | -21.13% | ||
| 1 Year | -34.59% | ||
| 5 Years | 36.03% |
ELV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 491.389 | |
| Number of Ratings | 23 | Current Quarters Estimate | 8.618 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | 34.48 | |
| Last Quarter’s Earnings | 9.16 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 33.04 | Next Fiscal Year Estimate | 39.178 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 20 | 21 | 20 |
| Mean Estimate | 8.62 | 4.62 | 34.48 | 39.18 |
| High Estimates | 9.98 | 6.06 | 36.12 | 41.60 |
| Low Estimate | 7.74 | 3.71 | 33.77 | 38.00 |
| Coefficient of Variance | 5.74 | 11.40 | 1.22 | 2.01 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 13 |
| OVERWEIGHT | 4 | 4 | 5 |
| HOLD | 6 | 6 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Elevance Health Inc. - ELV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Elevance Health Inc. - ELV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 12, 2025 | Ronald William Penczek CAO & Controller | 1,847 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $415.13 per share | 766,745.11 |
| Mar 6, 2025 | Felicia Farr Norwood EVP & President,Gov Health Ben | 11,549 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Ratnakar Lavu EVP, Chief Digital & Info Off | 8,902 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Morgan Kendrick EVP & President, Commercial | 10,116 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $396.3 per share | 4,008,970.80 |
| Mar 6, 2025 | Morgan Kendrick EVP & President, Commercial | 13,620 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Morgan Kendrick EVP & President, Commercial | 9,934 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Morgan Kendrick EVP & President, Commercial | 7,089 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $395.5 per share | 2,803,699.50 |
| Mar 6, 2025 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 11,549 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 26,004 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 21,791 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 18,756 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $395.5 per share | 7,417,998.00 |
| Mar 6, 2025 | Gail Koziara Boudreaux President and CEO; Director | 116,313 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $395.5 per share | 46,001,791.50 |
| Mar 6, 2025 | Felicia Farr Norwood EVP & President,Gov Health Ben | 31,939 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Felicia Farr Norwood EVP & President,Gov Health Ben | 27,726 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Felicia Farr Norwood EVP & President,Gov Health Ben | 24,691 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $395.5 per share | 9,765,290.50 |
| Mar 6, 2025 | Mark B. Kaye EVP & CFO | 13,713 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Mark B. Kaye EVP & CFO | 23,565 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Mark B. Kaye EVP & CFO | 19,961 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $395.5 per share | 7,894,575.50 |
| Mar 6, 2025 | Gail Koziara Boudreaux President and CEO; Director | 40,429 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Gail Koziara Boudreaux President and CEO; Director | 142,520 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Elevance Health Inc. in the News
Health insurer reverses course on anesthesia policy after receiving backlash
Anthem Blue Cross Blue Shield backtracked on imposing a anesthesia policy change in multiple states after the health insurer received strong backlash.